Literature DB >> 17176358

Treatment of psychosis: 30 years of progress.

I R De Oliveira1, M F Juruena.   

Abstract

BACKGROUND: Thirty years ago, psychiatrists had only a few choices of old neuroleptics available to them, currently defined as conventional or typical antipsychotics, as a result schizophrenics had to suffer the severe extra pyramidal side effects. Nowadays, new treatments are more ambitious, aiming not only to improve psychotic symptoms, but also quality of life and social reinsertion. Our objective is to briefly but critically review the advances in the treatment of schizophrenia with antipsychotics in the past 30 years. We conclude that conventional antipsychotics still have a place when just the cost of treatment, a key factor in poor regions, is considered. The atypical antipsychotic drugs are a class of agents that have become the most widely used to treat a variety of psychoses because of their superiority with regard to extra pyramidal symptoms. We can envisage different therapeutic strategies in the future, each uniquely targeting a different dimension of schizophrenia, be it positive, negative, cognitive or affective symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17176358     DOI: 10.1111/j.1365-2710.2006.00784.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  10 in total

Review 1.  Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology.

Authors:  Darrick T Balu; Irwin Lucki
Journal:  Neurosci Biobehav Rev       Date:  2008-08-19       Impact factor: 8.989

2.  Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.

Authors:  Kieran J Davey; Siobhain M O'Mahony; Harriet Schellekens; Orla O'Sullivan; John Bienenstock; Paul D Cotter; Timothy G Dinan; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2012-01-11       Impact factor: 4.530

3.  Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments.

Authors:  Darrick T Balu; Brian A Hoshaw; Jessica E Malberg; Sharon Rosenzweig-Lipson; Lee E Schechter; Irwin Lucki
Journal:  Brain Res       Date:  2008-03-21       Impact factor: 3.252

4.  Dopamine transporter endocytic determinants: carboxy terminal residues critical for basal and PKC-stimulated internalization.

Authors:  Ekaterina Boudanova; Deanna M Navaroli; Zachary Stevens; Haley E Melikian
Journal:  Mol Cell Neurosci       Date:  2008-06-25       Impact factor: 4.314

5.  Antipsychotic agents: efficacy and safety in schizophrenia.

Authors:  Arão Nogueira de Araújo; Eduardo Pondé de Sena; Irismar Reis de Oliveira; Mario F Juruena
Journal:  Drug Healthc Patient Saf       Date:  2012-11-29

6.  Safety and tolerability of antipsychotics: focus on amisulpride.

Authors:  Mario F Juruena; Eduardo Pondé de Sena; Irismar Reis de Oliveira
Journal:  Drug Healthc Patient Saf       Date:  2010-10-01

7.  Sertindole in the management of schizophrenia.

Authors:  Mario F Juruena; Eduardo Pondé de Sena; Irismar Reis de Oliveira
Journal:  J Cent Nerv Syst Dis       Date:  2011-05-17

8.  Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis.

Authors:  Jean-Michel Azorin; Susana Murteira; Karina Hansen; Mondher Toumi
Journal:  BMC Psychiatry       Date:  2008-03-14       Impact factor: 3.630

9.  Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine.

Authors:  Bong-Jo Kim; Jin-Wook Sohn; Chul-Soo Park; Gyu-Hee Hahn; Jun Koo; Yang-Deok Noh; Cheol-Soon Lee
Journal:  J Korean Med Sci       Date:  2008-08       Impact factor: 2.153

Review 10.  Aripiprazole: from pharmacological profile to clinical use.

Authors:  Guido Di Sciascio; Marco Andrea Riva
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-13       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.